Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone250-744-2487
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$460,000.00
Profitability
Miscellaneous
Employees39
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."
How were Aurinia Pharmaceuticals' earnings last quarter?
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02. The biotechnology company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%. View Aurinia Pharmaceuticals' Earnings History.
When is Aurinia Pharmaceuticals' next earnings date?
What price target have analysts set for AUPH?
7 analysts have issued 1-year target prices for Aurinia Pharmaceuticals' shares. Their forecasts range from $11.00 to $25.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 308.4% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.
What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.
What are Wall Street analysts saying about Aurinia Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (7/16/2019)
- 2. HC Wainwright analysts commented, "Buy ILJIN seeks effective control of Aurinia, or at least substantial influence, wholly disproportionate to its current holdings. Over the weekend, Aurinia’s largest shareholder (about 14% S/O), ILJIN SNT Co., Ltd. (private; Seoul, South Korea) launched a proxy contest to elect at least 3 directors to the upcoming Annual General Meeting (AGM) to be held on Wednesday, June 26, 2019. ILJIN is a life science-focused investment fund with a portfolio of positions in about 12 companies (according to its website), including Aurinia which appears to be its largest and longest holding, with a total of about $58M invested since 2010, according to ILJIN." (6/4/2019)
Has Aurinia Pharmaceuticals been receiving favorable news coverage?
News stories about AUPH stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -2.6 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Aurinia Pharmaceuticals.
Are investors shorting Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 7,270,000 shares, an increase of 9.2% from the August 30th total of 6,660,000 shares. Based on an average trading volume of 571,900 shares, the short-interest ratio is currently 12.7 days. Currently, 12.1% of the company's shares are short sold. View Aurinia Pharmaceuticals' Current Options Chain.
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Alder Biopharmaceuticals (ALDR), Pacira Biosciences (PCRX), Tricida (TCDA), Aimmune Therapeutics (AIMT), Insmed (INSM), Heron Therapeutics (HRTX), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Nabriva Therapeutics (NBRV), Opko Health (OPK), BELLUS Health (BLUSF), Turning Point Therapeutics (TPTX) and Enanta Pharmaceuticals (ENTA).
What other stocks do shareholders of Aurinia Pharmaceuticals own?
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Mr. Michael R. Martin, Co-Founder & COO
- Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
- Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
- Dr. Richard M. Glickman, Advisor (Age 61)
- Dr. Neil Solomons M.D., Chief Medical Officer
How do I buy shares of Aurinia Pharmaceuticals?
Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of AUPH stock can currently be purchased for approximately $4.04.
How big of a company is Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals has a market capitalization of $380.93 million and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.
What is Aurinia Pharmaceuticals' official website?
How can I contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]
MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
